## MOLECULAR CANCER RESEARCH

### TABLE OF CONTENTS

#### HIGHLIGHTS

- **359** Selected Articles from This Issue

#### REVIEWS

- **361** The MEK/ERK Network as a Therapeutic Target in Human Cancer
  Renee Barbosa, Lucila A. Acevedo, and Ronen Marmorstein

- **375** Y-Box Binding Protein-1: A Neglected Target in Pediatric Brain Tumors?
  Louisa Taylor, Ian D. Kerr, and Beth Coyle

- **388** Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer
  Tzuriel Sapir, David Shifteh, Moshe Pahmer, Sanjay Goel, and Radhashree Maitra

#### Cancer Genes and Networks

- **414** MYC Activity Inference Captures Diverse Mechanisms of Aberrant MYC Pathway Activation in Human Cancers
  Evelien Schaafsma, Yanding Zhao, Lanjing Zhang, Yong Li, and Chao Cheng

- **429** G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-κB Signaling Pathway
  Ting Sun, Keqiang Zhang, Rajendra P. Pangehi, Jun Wu, Wendong Li, Yong Du, Yuming Guo, Shyambabu Chaurasiya, Leonidas Arvanitis, and Dan J. Raz

- **441** N-Acetyl-L-cysteine Promotes Ex Vivo Growth and Expansion of Single Circulating Tumor Cells by Mitigating Cellular Stress Responses
  Teng Teng, Mohamed Kamal, Oibana Iriondo, Yonatan Amzaleg, Chunqiao Luo, Amal Thomas, Grace Lee, Ching-Ju Hsu, John D. Nguyen, Irene Kang, James Hicks, Andrew Smith, Richard Spoeto, and Min Yu

#### CANCER "-OMICS"

- **451** 5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells
  Brian M. Reilly, Timothy Luger, Soo Park, Chan-Wang Jie, Edali Gonzalez-Avalos, Emily C. Wheeler, Minjung Lee, Laura Williamson, Tiffany Tanaka, Dinh Diep, Kun Zhang, Yun Huang, Anjana Rao, and Rafael Bejar

- **465** Characterization of Clonal Evolution in Microsatellite Unstable Metastatic Cancers through Multiregional Tumor Sequencing
  Russell Bonneville, Anoosha Paruchuri, Michele R. Wing, Melanie A. Krook, Julie W. Reeser, Hui-Zi Chen, Thuy Dao, Eric Samorodnitsky, Amy M. Smith, Lianbo Yu, Nicholas Nowacki, Wei Chen, and Sameek Roychowdhury

---

**Cancer Genes and Networks**

- **403** Differential Effects of Clinically Relevant N- versus C-Terminal Truncating CDKN1A Mutations on Cisplatin Sensitivity in Bladder Cancer
### TABLE OF CONTENTS

#### METABOLISM

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>475</td>
<td>Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum</td>
<td>Kathryn L. Penney, Svitlana Tyekucheva, Jacob Rosenthal, Habiba El Fandy, Ryan Carelli, Stephanie Borgstein, Giorgia Zadra, Giuseppe Nicola Fanelli, Lavinia Stefanizzi, Francesca Giunchi, Mark Pomerantz, Samuel Peisch, Hannah Coulson, Rosina Lis, Adam S. Kibel, Michelangelo Fiorentino, Renato Umeton, and Massimo Loda</td>
</tr>
</tbody>
</table>

#### SIGNAL TRANSDUCTION AND FUNCTIONAL IMAGING

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>485</td>
<td>AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors</td>
<td>Kavya Ramkumar, C. Allison Stewart, Kasey R. Cargill, Carminia M. Della Corte, Qi Wang, Li Shen, Lixia Diao, Robert J. Cardnell, David H. Peng, B. Leticia Rodriguez, You-Hong Fan, John V. Heymach, Jing Wang, Carl M. Gay, Don L. Gibbons, and Lauren A. Byers</td>
</tr>
</tbody>
</table>

#### TUMOR MICROENVIRONMENT AND IMMUNOBIOLOGY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>498</td>
<td>A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade</td>
<td>Yelena Lazdun, Han Si, Todd Creasy, Koustubh Ranade, Brandon W. Higgs, Katie Streicher, and Nicholas M. Durham</td>
</tr>
<tr>
<td>507</td>
<td>Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules</td>
<td>Yasuyo Sano, Toshimi Yoshida, Min-Kyung Choo, Yanek Jiménez-Andrade, Kathryn R. Hill, Katia Georgopoulos, and Jin Mo Park</td>
</tr>
<tr>
<td>516</td>
<td>Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity</td>
<td>Nikunj Gevariya, Gabriel Lachance, Karine Robitaille, Charles Joly Beauparlant, Lisa S. Beaudoin, Éric Fournier, Yves Fradet, Arnaud Droit, Pierre Julien, André Marette, Alain Bergeron, and Vincent Fradet</td>
</tr>
<tr>
<td>528</td>
<td>Hypoxic Induction of Exosome Uptake through Proteoglycan-Dependent Endocytosis Fuels the Lipid Droplet Phenotype in Glioma</td>
<td>Myriam Cerezo-Magaña, Helena C. Christianson, Toin H. van Kuppevelt, Karin Forsberg-Nilsson, and Mattias Belting</td>
</tr>
</tbody>
</table>

---

**ABOUT THE COVER**

DNA methylation is commonly dysregulated in a wide array of cancers, and numerous therapeutics have been developed to target this pathway. 5-Azacytidine is a DNA hypomethylating agent that can be particularly effective treatment in TET2-mutated myelodysplastic syndrome patients. The cover depicts hexagonal bins representing the density of CpG loci in a differential analysis of DNA methylation comparing targeted bisulfite sequencing data from TET2 wild-type and TET2 knockout human erythroleukemia cell lines (density gradient from red to blue, with red indicating larger number of CpG loci falling within the hexagonal bin and blue indicating a lesser number). The authors found that TET2 is essential for maintaining low levels of DNA methylation at erythroid-specific transcriptional enhancers, and that 5-Azacytidine can counteract aberrant hypermethylation of these enhancers when TET2 is mutated. For more information, see the article on page 451.